What are the appropriate next steps for a 34‑year‑old woman with Ehlers‑Danlos syndrome, mast‑cell activation syndrome, postural orthostatic tachycardia syndrome, low‑normal immunoglobulin A and G, recurrent ear and respiratory infections, and non‑immune measles and mumps despite two childhood MMR doses?

Evaluation and Management of Low-Normal Immunoglobulins with Vaccine Failure in hEDS

This patient requires functional antibody testing with pneumococcal polysaccharide vaccine challenge to determine whether she has specific antibody deficiency (SAD), which would explain both her recurrent infections and MMR vaccine failure. 1

Immediate Next Steps

1. Assess Specific Antibody Production

• Measure pre-vaccination titers to MMR antigens (measles, mumps, rubella IgG) to document baseline levels before any revaccination. 1

• Administer pneumococcal polysaccharide vaccine (PPSV23) and measure serotype-specific antibody responses 4–6 weeks post-vaccination. 1

• Diagnostic thresholds for pneumococcal response in adults >6 years:

  • Normal response: Concentration >1.3 mg/mL for >70% of serotypes tested with a 2-fold increase for >70% of serotypes 1
  • Moderate impairment: Concentration >1.3 mg/mL for <70% of serotypes 1
  • Severe impairment: Concentration >1.3 mg/mL for <2 serotypes 1

• Measure IgG subclasses (IgG1, IgG2, IgG3, IgG4) given her low-normal total IgG, recurrent respiratory infections, and vaccine failure—this pattern suggests possible IgG subclass deficiency (IGGSD). 1

2. Confirm and Repeat Immunoglobulin Levels

• Repeat total IgG, IgA, and IgM levels at least once, separated by ≥1 month from the initial measurement, to confirm persistent low-normal values and exclude laboratory error. 1

• Her IgG of 812 mg/dL and IgA of 79 mg/dL are both in the low-normal range; persistent values at this level combined with recurrent infections and vaccine failure warrant further investigation. 1

Clinical Context and Differential Diagnosis

Why Functional Testing is Critical

• Total immunoglobulin levels alone are insufficient to diagnose antibody deficiency when they fall in the low-normal range. 1

• Specific antibody deficiency (SAD) is defined by impaired antibody responses to polysaccharide antigens despite normal or near-normal total immunoglobulin levels. 1

• MMR vaccine failure (non-immune to measles and mumps despite two documented doses) is a red flag for impaired protein antigen responses and suggests a broader antibody production defect. 1, 2

• Recurrent respiratory and ear infections in childhood are the hallmark clinical manifestation of antibody deficiency, particularly SAD and IGGSD. 1

hEDS and Immune Dysfunction

• Immunoglobulin deficiency occurs in 43% of patients with suspected mast cell activation disease, and 19% of patients with hEDS/HSD have both immunoglobulin deficiency and MCAD. 3

• The combination of hEDS, POTS, MCAS, and immunoglobulin deficiency represents a recognized clinical phenotype, though the mechanistic relationship remains under investigation. 3, 4, 5

• Screen for MCAS only if she has episodic multisystem symptoms (≥2 organ systems: flushing, urticaria, wheezing, GI symptoms, cardiovascular symptoms). Baseline serum tryptase should be obtained only in this context. 1, 6

Management Algorithm Based on Test Results

If Pneumococcal Response is Impaired (<70% protective titers)

• Diagnosis: Specific Antibody Deficiency (SAD) 1

• Consider prophylactic antibiotics (e.g., amoxicillin 250–500 mg daily or azithromycin 250 mg three times weekly) if infections are frequent and negatively affect quality of life. 1

• Trial of IgG replacement therapy should be considered if:

  • Aggressive antibiotic therapy and prophylaxis fail 1
  • Intolerable side effects or hypersensitivity to antibiotics occur 1
  • Infections continue to impair quality of life despite conservative management 1

• Screen for anti-IgA antibodies before initiating IgG replacement, given her low-normal IgA (79 mg/dL), to assess risk of infusion reactions. 1

If IgG Subclasses are Low (Particularly IgG2)

• Diagnosis: IgG Subclass Deficiency (IGGSD) if one or more subclasses are <5th percentile on two separate measurements ≥1 month apart. 1

• IgG2 deficiency is commonly associated with impaired polysaccharide responses and recurrent sinopulmonary infections. 1

• Management principles for IGGSD follow those for SAD: prophylactic antibiotics first, then cautious trial of IgG replacement in selected patients with refractory infections. 1

Regarding MMR Revaccination

• Do not revaccinate with MMR until functional antibody testing is complete. 1, 2

• If she has documented SAD or IGGSD with impaired protein antigen responses, a third MMR dose is unlikely to generate protective immunity and may be futile. 1, 2

• If functional testing is normal, she may receive a third MMR dose, though this is off-label (standard dosing is two doses). 2

• IgG replacement therapy (if initiated for SAD/IGGSD) will provide passive immunity to measles and mumps through donor antibodies. 1

Common Pitfalls to Avoid

• Do not diagnose immunodeficiency based solely on low-normal immunoglobulin levels without functional testing—this leads to overdiagnosis. 1

• Do not measure IgG subclasses in isolation; always measure all four subclasses simultaneously, and confirm abnormalities on repeat testing. 1

• Do not initiate IgG replacement therapy without documented functional antibody deficiency—this is costly, invasive, and exposes the patient to unnecessary risks. 1

• Do not routinely test for MCAS in patients with isolated GI symptoms or POTS; testing is indicated only for episodic multisystem involvement. 1, 6

• Avoid labeling transient hypogammaglobulinemia of infancy (THI) in adults—this diagnosis applies only to children and resolves by age 5 years. 1

Monitoring and Follow-Up

• Repeat immunoglobulin levels annually if initial functional testing is normal but infections persist. 1

• Some patients with IGGSD or SAD can evolve into more severe phenotypes (e.g., common variable immunodeficiency) over time, requiring longitudinal surveillance. 1

• If IgG replacement is initiated, monitor trough IgG levels to ensure adequate dosing and assess for rising endogenous production (which may indicate transient deficiency). 1